Lumida
/OCGN
⌘K
Ocugen Inc

Ocugen Inc

OCGN
$1.36USD-0.73%-0.01 today

MARKET CAP

460.4M

P/E (TTM)

FWD P/E

DAY RANGE

$1 – $1

52W RANGE

$1
$3

AI Summary

Stalk
StalkMedium

OCGN remains in a Stage 2 advancing corrective reset with the active Bullish Pivot Point confirming structural repair. The recent volume-led breakout above resistance is positive, but price is extended above the rising 9/21 EMA zone and near overhead supply. Medium-term bias stays bullish in line with Stage 2, while short-term timing is unfavorable. We defer execution and stalk for a pullback into the supported EMA zone for cleaner entry. Primary risks include failure to hold the 9/21 EMA support and a reversal at the overhead resistance band.

  • OCU400 BLA rolling submission starts Q3 2026 for 2027 commercialization
  • OCU400 targets up to 98% of retinitis pigmentosa patients addressing broad mutations
  • Operating loss $19.4M and $0.06 net loss per share in Q1 2026
Full analysis →
Insider Trades8 trades
DateSideTickerInsiderRoleSharesPriceMkt Cap52W High52W LowValue% ChgRuleAI View
Jun 15, 2026BuyOCGNTreerita Essalima Johnson-GreeneChief Financial Officer21,000$1.23$460.4M-50.09%+46.08%$25.8K+4.20%Stalk
Jan 3, 2025SellOCGNArun Upadhyay41,633$0.89$460.4M-50.09%+46.08%$37.2K-3.86%Stalk
Jan 3, 2025SellOCGNShankar MusunuriChief Executive Officer177,146$0.89$460.4M-50.09%+46.08%$158.5K-4.62%Stalk
Sep 16, 2024SellOCGNArun Upadhyay842$1.17$460.4M-50.09%+46.08%$985.14-0.24%Stalk
Jun 17, 2024SellOCGNArun Upadhyay917$1.42$460.4M-50.09%+46.08%$1.3K-0.26%Stalk
Jan 3, 2024SellOCGNArun Upadhyay41,633$0.65$460.4M-50.09%+46.08%$27.2K-10.64%Stalk
Jan 3, 2024SellOCGNShankar MusunuriChief Executive Officer180,204$0.65$460.4M-50.09%+46.08%$117.7K-8.23%Stalk
Sep 16, 2023SellOCGNArun Upadhyay842$0.41$460.4M-50.09%+46.08%$345.22-0.21%Stalk